Insertional Gene Activation by Lentiviral and Gammaretroviral Vectors
Open accessThe DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Abstract
Gammaretroviral and lentiviral vectors are promising tools for gene therapy, but they can be oncogenic. The development of safer vectors depends on a quantitative assay for insertional mutagenesis. Here we report a rapid, inexpensive, and reproducible assay which uses a murine cell line to measure the frequency of interleukin-3 (IL-3)-independent mutants. Lentiviral and gammaretroviral vectors cause insertional mutagenesis at similar frequencies; however, they use different mechanisms. Human immunodeficiency virus (HIV)-based vectors generate mutants by insertion only into the growth hormone receptor ( Ghr ) locus. The HIV enhancer/promoter is active in the absence of the HIV Tat protein in this locus, and an HIV/ Ghr spliced transcript expresses GHR and cells respond to GH. Deletion of the enhancer/promoter in a self-inactivating HIV-based vector prevents this mechanism of insertional mutagenesis. In contrast, gammaretroviral vectors insert into other loci, including IL-3 and genes identified as common insertion sites in the Retroviral Tagged Cancer Gene Database (RTCGD).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“However, insertional mutagenesis has been found in clinical trials with lentiviral vectors, prompting a detailed study of genotoxicity assays of all integrated vectors [76,77].”
From Non-Integrating Lentiviral Vectors in Clinical Applications: A Glance Through (2022) · cites this paper as [77]
Citations
Cites
LMO2 -Associated Clonal T Cell Proliferation in Two Patients after Gene Therapy for SCID-X1
Hacein-Bey-Abina, S., Von Kalle, C., Schmidt, M., McCormack, M. P., Wulffraat, N., Leboulch, P., Lim, A., Osborne, C. S., Pawliuk, R., Morillon, E., et al. (2003) · Science · doi:10.1126/science.1088547 · Cited by 3,587 · cited 1×
“For example, patients with common gamma-chain deficiency treated with a gammaretroviral vector have developed leukemia following vector insertion in oncogenic loci (13).”
BackgroundGene Therapy of Human Severe Combined Immunodeficiency (SCID)-X1 Disease
Cavazzana-Calvo, M., Hacein-Bey, S., Basile, G. D. S., Gross, F., Yvon, E., Nusbaum, P., Selz, F., Hue, C., Certain, S., Casanova, J.-L., et al. (2000) · Science · doi:10.1126/science.288.5466.669 · Cited by 2,167 · cited 2×
“Because such vectors integrate into cellular DNA, transduction of patients’ bone marrow stem cells has been used to modify progeny cells of the hematopoietic system, leading to correction of inherited immunodeficiencies (1, 6, 23).”
BackgroundMethodTranscription Start Regions in the Human Genome Are Favored Targets for MLV Integration
Wu, X., Li, Y., Crise, B., & Burgess, S. M. (2003) · Science · doi:10.1126/science.1083413 · Cited by 1,305 · cited 6×
“G18 2 N Il3 16187 11 2,607 bp downstream Cytokine/growth factor activity N Fbxo9 71538 9 3,183 bp upstream Ubiquitin-protein ligase activity N Ick 56542 5,744 bp upstream Protein kinase activity, signal transduction Control CNCG 2 1 Y Tpm3 59069 3 8,408 bp, intron 2-3 Regulation of muscle contraction 1 CNCG 6 1 N Mll2…”
BackgroundMethodInfluentialOtt, M. G., Schmidt, M., Schwarzwaelder, K., Stein, S., Siler, U., Koehl, U., Glimm, H., Kühlcke, K., Schilz, A., Kunkel, H., et al. (2006) · Nature Medicine · doi:10.1038/nm1393 · Cited by 1,051 · cited 2×
“Because such vectors integrate into cellular DNA, transduction of patients’ bone marrow stem cells has been used to modify progeny cells of the hematopoietic system, leading to correction of inherited immunodeficiencies (1, 6, 23).”
BackgroundRetroviral DNA Integration: ASLV, HIV, and MLV Show Distinct Target Site Preferences
Mitchell, R. S., Beitzel, B. F., Schroder, A. R. W., Shinn, P., Chen, H., Berry, C. C., Ecker, J. R., & Bushman, F. D. (2004) · PLoS Biology · doi:10.1371/journal.pbio.0020234 · Cited by 976 · cited 1×
“However, MLV tends to integrate near the transcription start site, and HIV shows a stronger preference for expressed genes (20, 38).”
BackgroundCorrection of ADA-SCID by stem cell gene therapy combined with nonmyeloablative conditioning
Aiuti, A., Slavin, S., Aker, M., Ficara, F., Deola, S., Mortellaro, A., Morecki, S., Andolfi, G., Tabucchi, A., Carlucci, F., et al. (2002) · Science · doi:10.1126/science.1070104 · Cited by 975 · cited 1×
“Because such vectors integrate into cellular DNA, transduction of patients’ bone marrow stem cells has been used to modify progeny cells of the hematopoietic system, leading to correction of inherited immunodeficiencies (1, 6, 23).”
BackgroundMontini, E., Cesana, D., Schmidt, M., Sanvito, F., Ponzoni, M., Bartholomae, C., Sergi, L. S., Benedicenti, F., Ambrosi, A., Di Serio, C., et al. (2006) · Nature Biotechnology · doi:10.1038/nbt1216 · Cited by 701 · cited 1×
“Retroviral-vector insertional oncogenesis has been quantitated in mice either by using vectors expressing an oncogene (11, 18) or mutant, tumor-prone mice (22, 29).”
BackgroundA transient three-plasmid expression system for the production of high titer retroviral vectors
Soneoka, Y., Cannon, P. M., Ramsdale, E. E., Griffiths, J. C., Romano, G., Kingsman, S. M., & Kingsman, A. J. (1995) · Nucleic Acids Research · doi:10.1093/nar/23.4.628 · Cited by 690
Palacios, R., & Steinmetz, M. (1985) · Cell · doi:10.1016/s0092-8674(85)80053-2 · Cited by 688
Gene transfer in humans using a conditionally replicating lentiviral vector
Levine, B. L., Humeau, L. M., Boyer, J., MacGregor, R.-R., Rebello, T., Lu, X., Binder, G. K., Slepushkin, V., Lemiale, F., Mascola, J. R., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0608138103 · Cited by 501 · cited 1×
“In a recent AIDS gene therapy clinical trial, a WT HIV-1 LTR lentiviral vector was used to drive antisense RNA against the HIV-1 envelope, so that Tat would activate expression in HIVinfected cells (17).”
Method
Cited by
Items 101–145 of 145
Moonmuang, S., Saoin, S., Chupradit, K., Sakkhachornphop, S., Israsena, N., Rungsiwiwut, R., & Tayapiwatana, C. (2018) · Bioscience Reports · doi:10.1042/bsr20181109 · Cited by 5
Re-structuring lentiviral vectors to express genomic RNA via cap-dependent translation
Counsell, J. R., Brabandere, G. D., Karda, R., Moore, M., Greco, A., Bray, A., Diaz, J. F. A., Perocheau, D. P. B., Mock, U., & Waddington, S. N. (2020) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2020.12.005 · Cited by 5
Themis, M. (2012) · Methods in molecular biology · doi:10.1007/978-1-61779-873-3_16 · Cited by 4
Baiamonte, E., Spinelli, G., Maggio, A., Acuto, S., & Cavalieri, V. (2016) · Nucleic Acid Therapeutics · doi:10.1089/nat.2016.0614 · Cited by 4
“Nonetheless, lentivectors also display enhancer-mediated dysregulation of neighboring genes in animal models of metabolic diseases [22,23].”
Synthetic Biology Industry: Biosafety Risks to Workers
Murashov, V. V., Howard, J., & Schulte, P. A. (2019) · Risk, systems and decisions · doi:10.1007/978-3-030-27264-7_8 · Cited by 4
Targeted genome editing for the correction or alleviation of primary Immunodeficiencies
Sipe, C. J., Vázquez, P. N. C., Skeate, J. G., McIvor, R. S., & Moriarity, B. S. (2021) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2021.03.001 · Cited by 4
Farraha, M., Rao, R., Igoor, S., Le, T. Y. L., Barry, M. A., Davey, C. G., Kok, C., Chong, J. J. H., & Kizana, E. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23169230 · Cited by 4
“Other vectors, such as lentivirus vectors, are n t cardi tropic and carry an attendant risk of insertional muta enesis [38,39].”
BackgroundRamamurthy, R. M., Rodriguez, M., Ainsworth, H. C., Shields, J. E., Meares, D., Bishop, C. E., Farland, A. M., Langefeld, C. D., Atala, A., Doering, C. B., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.954984 · Cited by 4
Engineering viral vectors for in vivo CAR-T generation: Advances, challenges, and opportunities
Yang, P., Ma, Z., Liu, G., Shen, Y., Bai, Z., Zheng, S., & Xu, Z. (2026) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2026.105209 · Cited by 4
Halagali, P., Seenivasan, R., Sreedevi, A., Ligade, V. S., Bugadannavar, P., Sharma, H., Nand, S., & Tippavajhala, V. K. (2026) · 3 Biotech · doi:10.1007/s13205-026-05016-2 · Cited by 5
“In animal models and cel - lular systems susceptible to oncogenesis, lentiviruses cause insertional mutagenesis (Bokhoven et al. 2009 ), although, in general, they are less mutagenic than their oncoretrovirus counterparts (Hematti et al. 2004; Montini et al. 2009 ).”
Zhou, X., Liu, Q., Wang, D., Zhang, X., Emery, D. W., & Li, C. L. (2017) · Cytogenetic and Genome Research · doi:10.1159/000464315 · Cited by 3
“In a previous study, aberrant lentiviral vector transcription was directly associated with malignant transformation [Bokhoven et al., 2009].”
BackgroundMorgan, J. E., & Alameddine, H. S. (2012) · InTech eBooks · doi:10.5772/30831 · Cited by 3
“Although lentiviruses integrate preferentially into active transcription sites (Ciuffi, 2008) the development of third generation lentiviruses with advanced SIN design (Bokhoven et al. 2009), physiological”
BackgroundMontiel-Equihua, C., Thrasher, A. J., & Gaspar, H. B. (2009) · Stem Cells and Cloning Advances and Applications · doi:10.2147/sccaa.s5570 · Cited by 3
Eipers, P. G., Salazar-Gonzalez, J. F., & Morrow, C. D. (2010) · Virology · doi:10.1016/j.virol.2010.11.001 · Cited by 3
“Alternatively, it is possible the insertion of the HIV-1 genome could impact the host cell promoter, which might provide a selective advantage to the cell (Bokhoven et al., 2009).”
BackgroundVisualizing H 2 O 2 and NO in endothelial cells: strategies and pitfallsPreprint
Altun, H. Y., Seçilmiş, M., Çağlar, T. A., Vatandaşlar, E., Öztürk, G., Vilain, S., & Eroğlu, E. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.02.15.528776 · Cited by 3
“(F) Representative images of cells expressing O-geNOp in different binning configurations (G) O-geNOp signals in response to 1 μM of NOC-7 using different camera binning (H) Close-up curves show the dynamic of O-geNOp signals (I) XY graph was plotted using the rates of O-geNOp fluorescence intensity change with respec…”
MethodInfluentialTakayama, K., & Torashima, T. (2009) · Journal of NeuroVirology · doi:10.3109/13550280903214091 · Cited by 2
“Nevertheless, recent study has identified the use of LVs as a risk factor although they are SILVs ( Bokhoven et al, 2009 ).”
BackgroundClinical Grade Lentiviral Vectors
Kochan, G. T., Escors, D., Stephenson, H. N., & Breckpot, K. (2012) · SpringerBriefs in biochemistry and molecular biology · doi:10.1007/978-3-0348-0402-8_5 · Cited by 2
Genetics of Hypertension and Cardiovascular Disease
Katsuya, T., Harrap, S. B., & Ogihara, T. (2010) · International Journal of Hypertension · doi:10.4061/2010/951254 · Cited by 3
Müller, L., Milsom, M. D., & Williams, D. A. (2010) · Springer eBooks · doi:10.1007/978-1-4419-7656-7_6 · Cited by 2
Engineered Viruses as Vaccine Platforms
Folgori, A., & Capone, S. (2012) · Springer eBooks · doi:10.1007/978-94-007-4543-8_4 · Cited by 3
“Despite the desirable advantage of LVs to effectively deliver transgenes into DCs, vector integration in the host cell genome has provoked safety concerns over the consequences of insertional mutagenesis (Bokhoven et al. 2009 ; Montini et al. 2006 ) .”
BackgroundRetroviruses as Tools to Identify Oncogenes and Tumor Suppressor Genes
Neil, J. C., & Stewart, M. A. (2010) · Springer eBooks · doi:10.1007/978-0-387-09581-3_10 · Cited by 2
Mazurek, M., Mlynarski, W. M., & Grzela, D. P. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1720048 · Cited by 1
Gene Therapy of CNS Disorders Using Recombinant AAV Vectors
Murlidharan, G., Samulski, R. J., & Asokan, A. (2016) · Springer eBooks · doi:10.1007/978-1-4899-7654-3_2 · Cited by 1
Introducing a Novel Method of Intravascular Adeno-associated Virus-mediated Gene Delivery.
Zh, F., Hosaka, K., Manfredsson, F. P., & Hoh, B. L. (2018) · PubMed · Cited by 2
Development of Retroviral and Lentiviral Vectors
Escors, D., Kochan, G. T., Stephenson, H. N., & Breckpot, K. (2012) · SpringerBriefs in biochemistry and molecular biology · doi:10.1007/978-3-0348-0402-8_2 · Cited by 2
Vesiculovirus G protein-based stable cell lines for continuous lentiviral vector production
Tijani, M. (2018) · UCL Discovery (University College London) · Cited by 1
Baum, C. (2010) · Human Gene Therapy · doi:10.1089/hum.2010.1317
“…al. , 2008; Arumugam et al. , 2009; Bokhoven et al. , 2009; Maruggi et al. , 2009; Modlich et al. , 2009), potentially leading to clonal dominance (Bokhoven et al. , 2009; Modlich et al. , 2009); and studies in mice have indicated that HSCs, as compared with more mature hematopoietic cell…”
Calero-Garcia, M., & Gaspar, H. B. (2014) · Current Pediatrics Reports · doi:10.1007/s40124-014-0069-1
Uchibori, C. (1975) · PubMed
Biology of AAV Vectors in the Central Nervous System
Murlidharan, G. (2016) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/cr64-be62
Gene therapy for methylmalonic aciduria.
Wong, E. S. Y. (2012) · Adelaide Research & Scholarship (AR&S) (University of Adelaide)
A novel cell and gene therapy approach for Friedreich's ataxia
Shaban, E. (2020) · Brunel University Research Archive (BURA) (Brunel University London)
Lentivirus-mediated knockdown of Galectin-10 and Foxp3 in human immune cells
Zidan, M. H. (2013) · Gutenberg Open Science · doi:10.25358/openscience-2749
Viral vectors for CNS disorders
Gray, S. J., Samulski, R. J., & Kalburgi, S. N. (2015) · doi:10.4155/fseb2013.13.23
MMEJ-mediated IDLV knock-in via CRISPR/Cas9 in human hematopoietic stem/progenitor cells.
Sakkal, A. (2023) · theses.fr (ABES) · doi:10.70675/678681caza0bdz47cbz8307zddd952dfde91
Developing a novel feeding strategy for enhanced lentiviral vector production
Patel, H. (2023) · UCL Discovery (University College London)
Daneshparvar, A., Jamhiri, I., Razban, V., Fallahi, J., Hamidizadeh, N., moghtaderi, B., & Dianatpour, M. (2024) · Medical Laboratory Journal · doi:10.66224/mlj.18.5.34
“Nevertheless, lentiviruses can enter the host cell's nucleus and insert their genome into the host's genome without requiring cell division (37,42,44,45).”
Approaching a Tat-Rev independent HIV-1 clone towards a model for research
Vera Ortega, W. (2018) · Enlighten: Theses (The University of Glasgow)
Sickle Cell Disease: Historical Overview and Current Therapies
Babatunde, O. O., Bibby, M. G., Atala, A., Almeida-Porada, G. D., & Porada, C. D. (2026) · Prenatal Diagnosis · doi:10.1002/pd.70195
Singh, R. D., Calvoli, M., & Kim, K. K. (2026) · Advanced Science · doi:10.1002/advs.77370
“Since such vectors contain a strong promoter and the integration is not controlled, they can potentially alter the chromatin arrangement and expression patterns of genes, including oncogenes and tumor suppressors [ 273–276 ].”
Evaluation of Anti-HIV-1 HSPC-Based Gene Therapy with Negative Selection Marker in Pigtail Macaques
Zhang, J., Murray, J., Mu, W., Venugopal, S., Yim, E., Einhaus, T., Radtke, S., Peterson, C. W., Kiem, H., & An, D. S. (2026) · Viruses · doi:10.3390/v18101133
Development and application of non-integrating lentiviral vectors for gene therapy
Apolonia, L. (2009) · UCL Discovery (University College London) · Cited by 1
Metadata
- Authors
- Bokhoven, M., Stephen, S. L., Knight, S., Gevers, E. F., Robinson, I. C., Takeuchi, Y., & Collins, M. K.
- Affiliations
- University College London (GB)
- National Institute for Medical Research (GB)
- Corresponding author
- Collins, Mary K.
- Venue
- Journal of Virology
- Publisher
- American Society for Microbiology
- Published
- 2009-01
- Volume
- 83
- Issue
- 1
- Pages
- 283-294
- ISSN
- 0022-538X (ISSN-L)
- 1098-5514
- PMC
- PMC2612344
- OpenAlex
- W2134056794
- Semantic Scholar
- 00dac6f887ef7c0e93ed3839c2a8065d747910a7
- Cited by
- 138
- References
- 39
- Citations by year
- 2026: 4 · 2025: 3 · 2024: 6 · 2023: 2 · 2022: 9 · 2021: 7 · 2020: 4 · 2019: 6 · 2018: 8 · 2017: 7 · 2016: 8 · 2015: 8 · 2014: 8 · 2013: 9 · 2012: 12
- FWCI
- 6.86
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- journals.asm.org/non-commercial-tdm-license (tdm)
- Locations
- Journal of Virology (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Research Explorer (The University of Manchester) (publishedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Funders
- Health and Safety Executive
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › CRISPR and Genetic Engineering
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Keywords
- insertional mutagenesis, lentiviral vectors, gammaretroviral vectors, gene therapy safety, oncogenicity, HIV-based vectors, self-inactivating vectors, Tat protein, insertion site mapping
- MeSH terms
- Animals, Cell Line, Genetic Vectors, Genetic Therapy, Lentivirus, Mutagenesis, Insertional, Gammaretrovirus, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.